share_log

康希諾生物：股份發行人的證券變動月報表

CANSINOBIO: Monthly Return of Equity Issuer on Movements in Securities

HKEX ·  Jun 4 15:48
Summary by Futu AI
康希諾生物股份公司於2024年6月4日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年5月31日的公司股份變動情況。報告顯示，康希諾生物的H股（股份代號06185）和A股（股份代號688185）在報告期間內均無增減，H股和A股的結存數量分別維持在132,670,900股和114,778,999股。此外，公司確認在2024年5月期間沒有進行A股的回購活動。康希諾生物於2022年1月23日董事會通過的員工持股計劃或股權激勵計劃下的A股回購方案，自2022年2月7日至2022年12月1日期間回購的406,098股A股至今未注銷，並僅在特定情況下可進行注銷。
康希諾生物股份公司於2024年6月4日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年5月31日的公司股份變動情況。報告顯示，康希諾生物的H股（股份代號06185）和A股（股份代號688185）在報告期間內均無增減，H股和A股的結存數量分別維持在132,670,900股和114,778,999股。此外，公司確認在2024年5月期間沒有進行A股的回購活動。康希諾生物於2022年1月23日董事會通過的員工持股計劃或股權激勵計劃下的A股回購方案，自2022年2月7日至2022年12月1日期間回購的406,098股A股至今未注銷，並僅在特定情況下可進行注銷。
On June 4, 2024, CanSino Biologics Limited submitted the latest monthly report on securities changes to Hong Kong Exchanges and Clearing Limited, reporting on the changes in the company's shareholding up to May 31, 2024. The report shows that CanSino Biologics' H shares (stock code 06185) and A shares (stock code 688185) did not increase or decrease during the reporting period, and the remaining number of H shares and A shares remained at 132,670,900 and 114,778,999, respectively. In addition, the company confirmed that it did not carry out any repurchase activities for A shares in May 2024. The 406,098 A shares repurchased from the A-share repurchase plan under the employee shareholding plan or stock-based incentive plan passed by the board of directors of CanSino Biologics on January 23, 2022 have not been cancelled to date and can only be cancelled under specific circumstances.
On June 4, 2024, CanSino Biologics Limited submitted the latest monthly report on securities changes to Hong Kong Exchanges and Clearing Limited, reporting on the changes in the company's shareholding up to May 31, 2024. The report shows that CanSino Biologics' H shares (stock code 06185) and A shares (stock code 688185) did not increase or decrease during the reporting period, and the remaining number of H shares and A shares remained at 132,670,900 and 114,778,999, respectively. In addition, the company confirmed that it did not carry out any repurchase activities for A shares in May 2024. The 406,098 A shares repurchased from the A-share repurchase plan under the employee shareholding plan or stock-based incentive plan passed by the board of directors of CanSino Biologics on January 23, 2022 have not been cancelled to date and can only be cancelled under specific circumstances.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.